Skip to main content

Table 7 Results of one-way sensitivity analyses for base-case scenario

From: Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

  Values Estimated ICER
Base Case   $19420
Death hazard ratio of Met+SU to Met+DPP-4i 1.67 (−10%) $23760
Death hazard ratio of Met+SU to Met+DPP-4i 2.04 (+ 10%) $16760
Metformin treatment failure 0.035 (−25%) $19440
Metformin treatment failure 0.058 (+ 25%) $19560
Met+DPP-4i treatment failure 0.010 (−25%) $18970
Met+DPP-4i treatment failure 0.017 (+ 25%) $20010
Met+SU treatment failure 0.040 (−25%) $19410
Met+SU treatment failure 0.067 (+ 25%) $19590
Severe hypoglycemia in Met+SU 0.012 (−25%) $19500
Severe hypoglycemia in Met+SU 0.020 (+ 25%) $19500
Severe hypoglycemia in insulin glargine triple therapy 0.008 (−25%) $19500
Severe hypoglycemia in insulin glargine triple therapy 0.013 (+ 25%) $19500
Weight gain in the first year of Met+SU 0.383 (−25%) $19520
Weight gain in the first year of Met+SU 0.638(+ 25%) $19470
Myocardial infarction in Met+DPP-4i 0.003(−25%) $19380
Myocardial infarction in Met+DPP-4i 0.005(+ 25%) $19620
Heart failure in Met+DPP-4i 0.013(−25%) $19120
Heart failure in Met+DPP-4i 0.021(+ 25%) $19880
Stroke in Met+DPP-4i 0.002(−25%) $19470
Stroke in Met+DPP-4i 0.003(+ 25%) $19520
Heart failure in Met+SU 0.015(−25%) $19790
Heart failure in Met+SU 0.025(+ 25%) $19210
Stroke in Met+SU 0.015(−25%) $19660
Stroke in Met+SU 0.025(+ 25%) $19340
Costs of myocardial infarction $13970(−25%) $19430
Costs of myocardial infarction $23284(+ 25%) $19570
Costs of heart failure $10589(−25%) $19450
Costs of heart failure $17648(+ 25%) $19550
Costs of stroke $5954(−25%) $19660
Costs of stroke $9924(+ 25%) $19340
Costs of severe hypoglycemia $110(−25%) $19500
Costs of severe hypoglycemia $183(+ 25%) $19500
Costs of weight gain $217(−25%) $19520
Costs of weight gain $361(+ 25%) $19470
Costs of insulin glargine $2917(−20%) $20320
Costs of insulin glargine $4375(+ 20%) $18680
Death rate 0.019 (age 60–70) / 0.046 (age 71–80) / 0.096 (age 81–85) (−10%) $20780
Death rate 0.024 (age 60–70) / 0.057 (age 71–80) / 0.118 (age 81–85) (+ 10%) $18470
Time horizon 20 years (− 20%) $24250
Time horizon 30 years (+ 20%) $17580
Same cardiovascular event rates from 2 years after dual therapy MI; 0.004 / HF; 0.02 / Stroke; 0.02 $20420
Age at start of metformin monotherapy 55 (−8%) $21360
Age at start of metformin monotherapy 65 (+ 8%) $18120
  1. Acronyms: SU-sulfonylurea, DPP-4i-dipeptidyl peptidase-4 inhibitor, Met; metformin, MI-myocardial infarction, HF-heart failure